News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neurocrine Biosciences, Inc., GlaxoSmithKline Depression Drug GSK561679 Fails Mid-Stage Trial
September 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, Sept 14 (Reuters) - Neurocrine Biosciences Inc (NBIX.O) said an experimental depression drug it was developing with GlaxoSmithKline PLC (GSK.L) failed in a mid-stage trial to work better than a dummy drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
GlaxoSmithKline
MORE ON THIS TOPIC
Immunology and inflammation
J&J Ends Rheumatoid Arthritis Program After Disappointing Mid-Stage Data
August 29, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
August 28, 2025
·
2 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
August 27, 2025
·
1 min read
·
BioSpace Insights
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
·
3 min read
·
Dan Samorodnitsky
